Earlier quoted context omitted.
We need a new drug platform because the current model only satisfy the owners of the pharma corporations.
this has nothing to do with how Big Pharma develops drugs...
I don't believe this to be a contentious issue. It is well understood that the current model and associated costs of drug development provide little incentive for research and development of novel antibiotics.
In the words of the infectious diseases physician I referenced in another comment:
For the past 75 years, we've relied on a partnership between the federal government and big pharma to bring new antibiotics to market. And what we're seeing is that that partnership is dissolving, and it's dissolving for the simple reason that pharmaceutical companies increasingly are having trouble making a profit off of antibiotics.
The reason for that is if you think about an antibiotic, they are prescribed in short courses. And doctors are very stingy about doling them out. And even the best new antibiotic may wear out its welcome when the bacteria become resistant. So what we're finding is that these companies say, why would we want to make a product that doctors don't want to prescribe?
Now to address this, there are a number of policy proposals on the table. They're called push and pull incentives, which can entice these companies to stay in the antibiotic business. A push incentive might be something where you go to a company that's making billions of dollars and say we'll cut your corporate tax rate if you promise to invest some of those profits into new antibiotics. This is a sure-fire way to get more money into the pipeline. However, many people recoil at the idea of giving a tax break to a multi-billion dollar company.
https://www.npr.org/2019/06/02/729120288/-superbugs-book-chr...